Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPTFree Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $34.00 price objective on the stock.

Checkpoint Therapeutics Stock Up 5.6 %

Shares of NASDAQ:CKPT opened at $1.88 on Thursday. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62. The stock has a market cap of $67.10 million, a price-to-earnings ratio of -0.68 and a beta of 1.00. The firm’s 50 day moving average price is $1.74 and its 200 day moving average price is $2.00.

Checkpoint Therapeutics (NASDAQ:CKPTGet Free Report) last released its quarterly earnings data on Friday, March 22nd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.36). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts anticipate that Checkpoint Therapeutics will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Checkpoint Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Checkpoint Therapeutics by 92.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock valued at $26,000 after buying an additional 5,375 shares in the last quarter. Choreo LLC acquired a new position in Checkpoint Therapeutics in the fourth quarter valued at $44,000. Magnus Financial Group LLC purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter worth about $55,000. Lindbrook Capital LLC purchased a new position in shares of Checkpoint Therapeutics during the first quarter worth about $62,000. Finally, B. Riley Wealth Advisors Inc. increased its position in shares of Checkpoint Therapeutics by 9.4% during the third quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock worth $84,000 after purchasing an additional 4,205 shares in the last quarter. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Company Profile

(Get Free Report)

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

See Also

Analyst Recommendations for Checkpoint Therapeutics (NASDAQ:CKPT)

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.